Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

PRV

- PMLiVE

Evenity back on track with FDA panel blessing in osteoporosis

US drugs regulator first rejected the drug due to cardiovascular concerns

- PMLiVE

FDA expecting boom in cell and gene therapies

Pledges clampdown on developers working outside regulations

- PMLiVE

FDA moves into crisis mode as shutdown drags on

New drug appraisals already being affected

- PMLiVE

US government shutdown leaves FDA running on empty

Funding row means shutdown could break 21 day record

Sanofi reception

Sanofi and Regeneron re-jig immuno-oncology deal

Partners refocus around two promising bispecific candidates

- PMLiVE

FDA takes aim at pharma’s biosimilar-delaying tactics

Ever-rising cost of insulins also to be targeted

- PMLiVE

FDA clears Sandoz and Pear’s Opioid Use Disorder app

The app incorporates CBT to improve high relapse rates

- PMLiVE

As France protests, Sanofi takes axe to 670 jobs

Layoffs latest in restructuring programme

- PMLiVE

CHMP backs Sanofi’s all-oral sleeping sickness drug

Sanofi's drug and others given green light by EMA committee

- PMLiVE

Pfizer claims rapid FDA nod for Lorbrena

Green light is latest in a string of cancer drug approvals

Sanofi reception

Dupixent helps put Sanofi back on growth track

French drugs giant sees an 8% rise in vaccine sales

- PMLiVE

MS and cholesterol drugs picked for new UK rapid uptake push

Accelerated Access Collaborative aims to break down barriers to faster uptake

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links